Ming-yuan Chen

This study tests four different drug combinations in 208 adults with advanced nasopharyngeal cancer that has stopped responding to standard treatments, including PD-1 inhibitors. The goal is to see which combination best shrinks tumors and controls the disease. Participants will …

This study tests whether adding a targeted drug (MRG003) to precise radiation (SBRT) can better control or shrink EGFR-positive metastatic tumors that have spread to a few spots (up to 5). About 200 adults with controlled primary tumors will receive either standard therapy or the…

This study compares a lower dose of radiation (40.2Gy) to the standard dose (49.2Gy) for people with stage II nasopharyngeal cancer that responds well to chemotherapy and immunotherapy. The goal is to see if the lower dose can control the cancer just as well while causing fewer s…

This study is for people with advanced nasopharyngeal cancer (a type of head and neck cancer) whose tumors shrink significantly after initial chemotherapy and immunotherapy. It tests whether a lower dose of radiation therapy is as effective as the standard dose, with fewer side e…

This study is for people with nasopharyngeal cancer that has spread to other parts of the body. It compares two radiation approaches after full chemotherapy and immunotherapy: one that treats a smaller area and one that treats the standard larger area. The goal is to see if the s…

This study tests whether adding a targeted drug (becotatug vedotin) to standard immunotherapy works better than immunotherapy alone for people with a certain type of advanced head and neck cancer that can be removed by surgery. About 430 adults with EGFR-positive, CPS≥1 tumors wi…

This study tests a combination of three drugs (sintilimab, anlotinib, and a taxane chemotherapy) in 33 adults with nasopharyngeal cancer that has returned or spread and hasn't responded to prior treatments. The goal is to see if this combo can shrink tumors and control the diseas…